Most people shopping for weight loss medication online fixate on the monthly subscription fee and miss the actual total: medication cost, shipping, lab fees, and whether the provider even covers their state. The numbers look very different once all of that is on the table.

Here are six providers worth comparing seriously, ordered by overall value for cash-pay patients.

1. HealthRX

Verdict: Best overall for cash-pay price plus verified pharmacy transparency

Start with the pricing, because it is genuinely low relative to the telehealth field. Compounded semaglutide begins at $99 per month; compounded tirzepatide starts at $149. Once-weekly injections, no contract language buried in the fine print. Free overnight shipping reaches all 50 states.

What makes HealthRX stand out beyond price is that the pharmacy is actually named. Medication ships from Manifest Pharmacy in Greer, South Carolina, a 503A-compliant facility operating under USP-797 standards with lot-level tracking from preparation through delivery. That is a specific, verifiable detail most competitors skip entirely. The platform also carries LegitScript certification (certificate 50087439), which is an independent pharmacy verification standard.

The clinical process is online: complete a health assessment, a US board-certified physician reviews it in roughly 24 hours, and medication ships overnight after approval. The trials HealthRX references for efficacy context are real published data: tirzepatide produced roughly 21% average body weight reduction at 72 weeks in SURMOUNT-1, and semaglutide produced roughly 15% at 68 weeks in STEP 1. HealthRX is citing those trial outcomes, not claiming its compounded product replicates a branded drug.

One honest caveat: compounded medications are not FDA-approved, and the FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026. Choosing a provider with a named, 503A-certified pharmacy matters more now than it did two years ago.

Rating: Top pick for cash-pay access across all 50 states

2. FormBlends

Verdict: Strong choice if published purity data or a broader peptide catalog matters to you

FormBlends also operates a compounded GLP-1 telehealth model under physician oversight, dispensing through an FDA-registered 503A compounding pharmacy. The differentiator here is documentation. FormBlends publishes per-product testing results, including HPLC purity figures, mass spec identity confirmation, and endotoxin and sterility results with actual named numbers. That level of transparency is rare in this category.

Pricing is higher. Semaglutide is priced at approximately $299 per vial and tirzepatide at approximately $349. Ships to 47 states, so not quite universal coverage. FormBlends also carries a wider peptide catalog covering recovery, longevity, and cognitive support compounds under the same clinician model, which gives it a different kind of value for patients who want one provider across multiple goals.

The summary is simple. HealthRX wins on entry price and reach. FormBlends wins if you want third-party-style batch documentation sitting right on the product page, or if you are already interested in peptides beyond GLP-1s.

Rating: Best pick for published testing transparency and multi-category peptide access

3. Mochi Health

Verdict: Good monitoring, low compounded pricing, obesity medicine background

Mochi Health prices compounded semaglutide around $99 per month and tirzepatide around $199, with board-certified obesity medicine clinicians on the clinical side. The monitoring is more hands-on than bare-bones telehealth. For patients who want a clinician background specifically in obesity medicine rather than general practice, Mochi is worth a serious look.

Rating: Solid mid-range pick with clinical depth

4. Hims & Hers

Verdict: Recognizable brand, brand-name drugs now, higher price floor

After settling with Novo Nordisk in March 2026, Hims & Hers moved away from compounded GLP-1s and shifted to branded medications. Injectable Wegovy runs around $299 per month through the platform, oral options around $249, and Zepbound around $399. With insurance and a manufacturer savings card, costs can drop to near zero for some patients. Without insurance, the price gap versus cash-pay compounders is large.

Rating: Best for insured patients who want brand-name medications

5. Ro Body

Verdict: Insurance navigation handled, membership model, meds billed separately

Ro charges roughly $39 for the first month and $74 to $149 per month after that, with medication billed as a separate line item. Their prior authorization team actively works insurance approvals, which is genuinely useful for patients with coverage who do not want to manage that process themselves. Total cost varies widely depending on what the insurer covers.

Rating: Good fit for patients with insurance willing to do some work

6. PlushCare

Verdict: Cheapest membership, same-day availability, branded meds only

At roughly $19.99 per month for membership, PlushCare has one of the lowest platform fees in the category. Same-day visit availability is a real operational advantage. The trade-off is that it focuses on branded medications rather than compounded options, so cash-pay patients face higher medication costs unless insurance fills the gap.

Rating: Best entry point for insured patients who want fast access

Common Questions

What is actually the cheapest way to get semaglutide or tirzepatide through one of these platforms?

Cash-pay compounded options from providers like HealthRX or Mochi Health currently offer the lowest out-of-pocket starting points, around $99 per month for semaglutide. That figure covers medication and shipping but not any optional labs. Branded drugs through Hims & Hers or PlushCare cost far more without insurance covering most of it.

Does it matter which compounding pharmacy a telehealth provider uses?

Yes, more than most people realize. A 503A-designated pharmacy operates under state board oversight and must meet USP-797 sterility standards. Providers that name their pharmacy, like HealthRX naming Manifest Pharmacy specifically, let you verify that status independently through the FDA compounding database. Anonymous sourcing is a real red flag after the 2026 FDA warning letters.

If Hims & Hers no longer sells compounded GLP-1s, what changed for existing patients?

Following the March 2026 Novo Nordisk settlement, Hims & Hers shifted to dispensing branded medications only. Patients previously on compounded semaglutide through the platform would have needed to transition to Wegovy or Zepbound, which carry significantly higher list prices. Insurance coverage or manufacturer savings cards are what make those options workable for most people.

How does FormBlends justify charging $299 to $349 per vial when competitors charge $99 to $149 per month?

The price difference reflects documented batch testing. FormBlends publishes HPLC purity figures, mass spec identity data, and sterility results per product. That documentation costs money to produce. For patients who want verifiable purity data on file before injecting anything, the premium has a specific, concrete rationale rather than just brand positioning.

Which of these providers works if you live in a state that is not one of the 47 or 50 covered?

HealthRX and the branded-medication platforms (Hims & Hers, PlushCare, Ro) have the widest state footprints. FormBlends ships to 47 states, so three states are excluded. If you are in a coverage gap, confirming eligibility directly with the provider before completing any health intake is worth doing, since state-level prescribing rules change and provider coverage maps are not always updated in real time.

*Note: Compounded medications mentioned above are not FDA-approved finished drug products. Pricing and availability change frequently. Confirm current details directly with each provider.*

Sources

• FDA warning letters to telehealth compounding firms, early 2026 (FDA.gov official communications)
• SURMOUNT-1 trial (tirzepatide), *New England Journal of Medicine*, 2022
• STEP 1 trial (semaglutide), *New England Journal of Medicine*, 2021
• Novo Nordisk settlement announcement, March 9, 2026 (Novo Nordisk investor relations)
• LegitScript pharmacy certification database (legitscript.com)
• Manifest Pharmacy, Greer SC, 503A status (FDA compounding pharmacy database)